<DOC>
	<DOCNO>NCT02883543</DOCNO>
	<brief_summary>Eligible patient administer oral icotinib 125mg three time daily two month , responsive patient ( partial response stable disease ) randomize ( 1 : 1 : 1 ) receive icotinib plus concurrent radiotherapy , chemotherapy plus concurrent radiotherapy , icotinib monotherapy .</brief_summary>
	<brief_title>First-line Icotinib With Concurrent Radiotherapy NSCLC With EGFR Mutation</brief_title>
	<detailed_description>Eligible patient administer oral icotinib 125mg three time daily two month , responsive patient ( partial response stable disease ) randomize ( 1 : 1 : 1 ) receive icotinib plus concurrent radiotherapy , chemotherapy plus concurrent radiotherapy , icotinib monotherapy . The primary endpoint progression-free survival , incidence radiation-induced lung injury .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>Aged 18 75 year Pathologically document NSCLC Unresectable stage III oligometastasis ( less three metastasis lesion , brain metastasis permit ) stage IV confirm CT and/or MRI Positive EGFR mutation confirm ARMS At least 3month life expectancy KPS ≥ 70 Adequate hematological value : hemoglobin ≥ 100 g/L , absolute neutrophil count ≥ 1.5 x 109/L , platelet count ≥ 100 x 109/L Adequate hepatic function : bilirubin ≤ 1.5 x ULN , AST/ALT ≤ 1.5 x ULN Written inform consent patient registration protocolrelated procedure Previous radiotherapy Received investigational systemic drug within 4 week prior study entry Severe uncontrolled systemic disease Active autoimmune disease , document history autoimmune/acquired immune disease , history organ transplant Pregnant lactating , woman childbearing potential , unless use effective contraception determine investigator Any serious underlying medical ( e.g . active uncontrolled infection , active gastric ulcer , uncontrolled seizure ) , psychological condition , judgment investigator , may interfere plan staging , treatment followup , affect patient compliance place patient high risk treatmentrelated complication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>